Linking Baseline PSMA PETDerived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [ 177 Lu]Lu-PSMA-617: A Single-Center Retrospective Study
Journal of Nuclear Medicine · 2026-02 · 67 (2) · 246-252
DOI: 10.2967/jnumed.125.270916 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 04.12.2025. Verfasst von Vishnu Murthy und 18 weiteren Autor:innen. Beteiligte Einrichtung: Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles,…. Hauptthemen laut MEDLINE: Dipeptides, Heterocyclic Compounds, 1-Ring, Lutetium, Quality of Life. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
This study aimed to investigate whether quantitative parameters derived from baseline prostate-specific membrane antigen (PSMA) PET imaging can predict hematologic toxicity and patient-reported outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA-617.
Methods
This retrospective study analyzed data from the U.S. expanded-access program at UCLA (NCT04825652). We included 61 patients with mCRPC who received 177Lu-PSMA-617 between May 2021 and March 2022 and had available baseline PSMA PET scans, hematologic toxicity data, and patient-reported outcomes. Questionnaires included the Functional Assessment of Cancer Therapy-Prostate (FACT-P), the Brief Pain Inventory-Short Form (BPI-SF), and a xerostomia assessment, all completed at each treatment cycle. Baseline PSMA PET parameters-including volume, SUVmean, SUVmax, and total lesion PSMA (TLP; calculated by multiplying SUVmean by volume) for whole-body disease, bone disease, and salivary glands-were quantified using TRAQinform IQ. Associations between these imaging metrics and clinical outcomes were assessed using univariate and multivariate models.
Results
Multivariate Cox regression analysis showed that higher baseline bone tumor SUVmean was significantly associated with delayed onset of grade 3 or 4 hematologic toxicity (hazard ratio [HR], 0.59; 95% CI, 0.36-0.98; P = 0.040), suggesting a protective effect. Conversely, higher bone TLP was associated with earlier onset of severe toxicity (HR, 1.31; 95% CI, 1.00-1.71; P = 0.049). Elevated whole-body SUVmean at baseline was predictive of delayed deterioration in both FACT-P total scores (HR, 0.59; 95% CI, 0.43-0.83; P = 0.002) and BPI-SF pain intensity (HR, 0.66; 95% CI, 0.46-0.93; P = 0.019). Additionally, higher salivary gland SUVmean, SUVmax, and TLP were significantly associated with increased xerostomia severity (P = 0.002, P = 0.006, and P = 0.015, respectively) in multivariate linear mixed-effects modeling.
Conclusion
In this retrospective analysis of patients with mCRPC treated with 177Lu-PSMA-617, baseline quantitative PSMA PET parameters were associated with both treatment-related toxicities and patient-reported outcomes. Validation in a larger, prospective, multicenter cohort is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California.
- Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California; koichirokimura@mednet.ucla.edu.
- Department of Medicine Statistics Core, David Geffen School of Medicine at UCLA, Los Angeles, California.
- AIQ Solutions, Madison, Wisconsin.
- Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
- Department of Medicine, VA Greater Los Angeles, Los Angeles, California; and.
Zitieren
APA
Murthy, V., Kimura, K., Theus, L., Nguyen, A., Grogan, T. R., Lokre, O., Perk, T., Rettig, M. B., Drakaki, A., Shen, J., Thin, P., Nguyen, K., Lira, S., Nabong, R. M., Gardner, L., Gonzalez, B. D., Gafita, A., Czernin, J., & Calais, J. (2026). Linking Baseline PSMA PETDerived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [ 177 Lu]Lu-PSMA-617: A Single-Center Retrospective Study. Journal of Nuclear Medicine, 67(2), 246-252. https://doi.org/10.2967/jnumed.125.270916
Vancouver
Murthy V, Kimura K, Theus L, Nguyen A, Grogan TR, Lokre O, et al. Linking Baseline PSMA PETDerived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [ 177 Lu]Lu-PSMA-617: A Single-Center Retrospective Study. Journal of Nuclear Medicine. 2026;67(2):246-252. doi:10.2967/jnumed.125.270916
BibTeX
@article{Murthy2026,
author = {Murthy, Vishnu and Kimura, Koichiro and Theus, Lela and Nguyen, Andrew and Grogan, Tristan R and Lokre, Ojaswita and Perk, Timothy and Rettig, Matthew B and Drakaki, Alexandra and Shen, John and Thin, Pan and Nguyen, Kathleen and Lira, Stephanie and Nabong, Rejah Marie and Gardner, Linda and Gonzalez, Brian D and Gafita, Andrei and Czernin, Johannes and Calais, Jeremie},
title = {Linking Baseline PSMA PETDerived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [ 177 Lu]Lu-PSMA-617: A Single-Center Retrospective Study},
journal = {Journal of Nuclear Medicine},
year = {2026},
volume = {67},
number = {2},
pages = {246--252},
doi = {10.2967/jnumed.125.270916}
}
EUVIMED